SPRO — Spero Therapeutics Share News
0.000.00%
Last trade - 00:00- $64.64m
- $13.87m
- $66.80m
UK Stocks-Factors to watch on Sept 22 (updated)
GSK takes stake in Spero in deal for experimental UTI treatment
Brief: GSK And Spero Therapeutics Announce Exclusive License Agreement For Tebipenem HBR
Spero jumps on positive update for UTI drug after FDA meeting
Brief: Spero Therapeutics provides Tebipenem HBR Program Update following Type A meeting with the U.S. FDA
Brief: Spero Therapeutics Announces Second Quarter 2022 Operating Results And Provides Business Update
Spero Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
U.S. STOCKS ON THE MOVE-Netflix, Playtika, Shopify, Li Auto
U.S. STOCKS ON THE MOVE-Walgreens Boots Alliance, Velodyne Lidar, U.S. banks
U.S. STOCKS ON THE MOVE-Snowflake, Nike, oil companies
Spero Therapeutics falls as FDA declines to approve UTI drug
Brief: Spero Therapeutics Receives Complete Response Letter From U.S. Food And Drug Administration For Tebipenem HBr New Drug Application
U.S. FDA declines to approve Spero's urinary tract infection drug (updated)
Spero Therapeutics falls after FDA declines to approve UTI drug
U.S. FDA declines to approve Spero's urinary tract infection drug
Brief: Spero Therapeutics - On June 7, Co Entered Revenue Interest Termination Agreement With Healthcare Royalty Management
U.S. RESEARCH ROUNDUP-Helmerich and Payne, J B Hunt Transport Services, Stratasys
Spero Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Spero Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview